<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37240018</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis and Serum Lipid Level Association: A Systematic Review and Meta-Analytic Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8675</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24108675</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with unknown etiology. Many metabolic alterations occur during ALS progress and can be used as a method of pre-diagnostic and early diagnosis. Dyslipidemia is one of the physiological changes observed in numerous ALS patients. The aim of this study is to analyze the possible relationship between the rate of disease progression (functional rating scale (ALS-FRS)) and the plasma lipid levels at the early stage of ALS. A systematic review was carried out in July 2022. The search equation was "Triglycerides AND amyotrophic lateral sclerosis" and its variants. Four meta-analyses were performed. Four studies were included in the meta-analysis. No significant differences were observed between the lipid levels (total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol) and the ALS-FRS score at the onset of the disease. Although the number of studies included in this research was low, the results of this meta-analytic study suggest that there is no clear relationship between the symptoms observed in ALS patients and the plasma lipid levels. An increase in research, as well as an expansion of the geographical area, would be of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pardo-Moreno</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences-Ceuta, University of Granada, 51001 Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed-Mohamed</LastName><ForeName>Himan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences-Ceuta, University of Granada, 51001 Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suleiman-Martos</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio Andaluz de Salud, 18014 Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Rodriguez</LastName><ForeName>Juan Jos&#xe9;</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-9081-5366</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences-Ceuta, University of Granada, 51001 Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas-Dominguez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2070-8834</Identifier><AffiliationInfo><Affiliation>Department of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melguizo-Rodr&#xed;guez</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9176-6997</Identifier><AffiliationInfo><Affiliation>Department of Nursery, Faculty of Health Sciences-Ceuta, University of Granada, 51001 Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Urquiza</LastName><ForeName>Jos&#xe9; L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Nursery, Faculty of Health Sciences-Ceuta, University of Granada, 51001 Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermudez-Pulgarin</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Faculty of Biology, University of Seville, 41012 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Morales</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Physiology Area, Department of Biomedicine, Biotechnology and Public Health, Faculty of Medicine, University of C&#xe1;diz, 11003 C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P18-RT-3324</GrantID><Agency>Regional Government of Andalusia</Agency><Country/></Grant><Grant><GrantID>20-01293 and PECART-0096-2020</GrantID><Agency>Regional Government of Andalusia</Agency><Country/></Grant><Grant><GrantID>P20-01061</GrantID><Agency>Regional Government of Andalusia</Agency><Country/></Grant><Grant><GrantID>PID2019-110960GB-I00</GrantID><Agency>Ministry of Science and Innovation, Spain</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cholesterol</Keyword><Keyword MajorTopicYN="N">lipids</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37240018</ArticleId><ArticleId IdType="pmc">PMC10218314</ArticleId><ArticleId IdType="doi">10.3390/ijms24108675</ArticleId><ArticleId IdType="pii">ijms24108675</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B., Logroscino G., Boum&#xe9;diene F., Labrunie A., Couratier P., Babron M.C., Leutenegger A.L., Preux P.M., Beghi E. Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin. Eur. J. Epidemiol. 2016;31:229&#x2013;245. doi: 10.1007/s10654-015-0090-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0090-x</ArticleId><ArticleId IdType="pubmed">26458931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M., Bede P., Byrne S., Jordan N., Gallagher L., Wynne B., O&#x2019;Brien C., Phukan J., Lynch C., Pender N., et al. Cognitive changes predict functional decline in ALS: A population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597. doi: 10.1212/WNL.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Lynch C., Pender N., Hardiman O. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study. J. Neurol. Neurosurg. Psychiatry. 2012;83:102&#x2013;108. doi: 10.1136/jnnp-2011-300188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J.P.K., Visser A.E., D&#x2019;Ovidio F., Vermeulen R., Beghi E., Chio A., Veldink J.H., Logroscino G., van den Berg L.H., Hardiman O. A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR. Neurology. 2017;89:1283&#x2013;1290. doi: 10.1212/WNL.0000000000004390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004390</ArticleId><ArticleId IdType="pubmed">28835399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.D., Little J., Gomes J., Cashman N.R., Krewski D. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology. 2017;61:101&#x2013;130. doi: 10.1016/j.neuro.2016.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2016.06.015</ArticleId><ArticleId IdType="pubmed">27377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Kee Kwong K.C., Gregory J.M., Pal S., Chandran S., Mehta A.R. Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: A systematic review of in vitro studies. Brain Commun. 2020;2:fcaa121. doi: 10.1093/braincomms/fcaa121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa121</ArticleId><ArticleId IdType="pmc">PMC7566327</ArticleId><ArticleId IdType="pubmed">33094283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., van Doormaal P.T., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A., V&#xf5;sa U., de Jong S., Robinson M.R., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Laslo P., Lipski J., Nicholson L.F., Miles G.B., Funk G.D. GluR2 AMPA receptor subunit expression in motoneurons at low and high risk for degeneration in amyotrophic lateral sclerosis. Exp. Neurol. 2001;169:461&#x2013;471. doi: 10.1006/exnr.2001.7653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2001.7653</ArticleId><ArticleId IdType="pubmed">11358459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretschmer B.D., Kratzer U., Schmidt W.J. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol. 1998;358:181&#x2013;190. doi: 10.1007/PL00005241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00005241</ArticleId><ArticleId IdType="pubmed">9750003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.J., Wang K.Y., Wang W.C. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) Neuroscience. 2004;125:191&#x2013;201. doi: 10.1016/j.neuroscience.2004.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2004.01.019</ArticleId><ArticleId IdType="pubmed">15051158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Bovio G., Canosa A., Bertuzzo D., Galmozzi F., Cugnasco P., Clerico M., De Mercanti S., Bersano E., et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: A population-based study. JAMA Neurol. 2014;71:1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A., Martinelli I., Bello L., Querin G., Puthenparampil M., Ruggero S., Toffanin E., Cagnin A., Briani C., Pegoraro E., et al. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017;74:525&#x2013;532. doi: 10.1001/jamaneurol.2016.5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M., Ayd&#x131;n B., Unal S., Arga K.Y., Kazan D. Metabolic Biomarkers and Neurodegeneration: A Pathway Enrichment Analysis of Alzheimer&#x2019;s Disease, Parkinson&#x2019;s Disease, and Amyotrophic Lateral Sclerosis. Omics J. Integr. Biol. 2016;20:645&#x2013;661. doi: 10.1089/omi.2016.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2016.0106</ArticleId><ArticleId IdType="pubmed">27828769</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S.I., Baek S., Park J.S., Piao L., Oh K.W., Kim S.H. Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. J. Clin. Neurol. 2015;11:376&#x2013;382. doi: 10.3988/jcn.2015.11.4.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2015.11.4.376</ArticleId><ArticleId IdType="pmc">PMC4596112</ArticleId><ArticleId IdType="pubmed">26424237</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Turner M.R., Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K., O&#x2019;Reilly &#xc9;.J., Cortese M., Furtado J.D., Kolonel L.N., Le Marchand L., McCullough M.L., Paganoni S., Schwarzschild M.A., Shadyab A.H., et al. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2021;22:133&#x2013;143. doi: 10.1080/21678421.2020.1822411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822411</ArticleId><ArticleId IdType="pmc">PMC8004541</ArticleId><ArticleId IdType="pubmed">32985910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia R., Chen Q., Zhou Q., Zhang R., Jin J., Hu F., Liu X., Qin X., Kang L., Zhao S., et al. Characteristics of serum metabolites in sporadic amyotrophic lateral sclerosis patients based on gas chromatography-mass spectrometry. Sci. Rep. 2021;11:20786. doi: 10.1038/s41598-021-00312-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-00312-8</ArticleId><ArticleId IdType="pmc">PMC8531355</ArticleId><ArticleId IdType="pubmed">34675267</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu X.H., Wu J.J., Ren H.M., Wang J., Ding Z.T., Jiang Y.P. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp. Ther. Med. 2016;11:2095&#x2013;2106. doi: 10.3892/etm.2016.3210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2016.3210</ArticleId><ArticleId IdType="pmc">PMC4887813</ArticleId><ArticleId IdType="pubmed">27284291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A., Arachchige B.J., Henderson R., Pow D., Reed S., Aylward J., McCombe P.A. Elevated plasma levels of D-serine in some patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2021;22:206&#x2013;210. doi: 10.1080/21678421.2020.1832120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1832120</ArticleId><ArticleId IdType="pubmed">33908331</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F., Obi T., Shishido T., Akatsu H., Murayama S., Saito Y., Yoshida M., Hasegawa M. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci. Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C. What are the means of alimentary function supply and their indications in amyotrophic lateral sclerosis? Rev. Neurol. 2006;162:309&#x2013;319. doi: 10.1016/S0035-3787(06)75206-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0035-3787(06)75206-7</ArticleId><ArticleId IdType="pubmed">17128131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Calvo A., Ilardi A., Cavallo E., Moglia C., Mutani R., Palmo A., Galletti R., Marinou K., Papetti L., et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73:1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic S.I., Stevic Z., Dedic V., Stojanovic V.R., Milicev M., Lavrnic D. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol. Res. 2012;34:576&#x2013;580. doi: 10.1179/1743132812Y.0000000049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812Y.0000000049</ArticleId><ArticleId IdType="pubmed">22732100</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J., K&#xfc;hnlein P., Hendrich C., Kassubek J., Sperfeld A.D., Ludolph A.C. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J. Neurol. 2011;258:613&#x2013;617. doi: 10.1007/s00415-010-5805-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5805-z</ArticleId><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., Gonzalez De Aguilar J.L., Bonnefont-Rousselot D., Bittar R., Seilhean D., Hauw J.J., Lacomblez L., Loeffler J.P., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Hirayama T., Takazawa T., Kawabe K., Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: A cross-sectional study. Intern. Med. 2012;51:1501&#x2013;1508. doi: 10.2169/internalmedicine.51.7465.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.M., Kim H., Kim J.E., Park K.S., Sung J.J., Kim S.H., Lee K.W. Amyotrophic lateral sclerosis is associated with hypolipidemia at the presymptomatic stage in mice. PLoS ONE. 2011;6:e17985. doi: 10.1371/journal.pone.0017985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017985</ArticleId><ArticleId IdType="pmc">PMC3064597</ArticleId><ArticleId IdType="pubmed">21464953</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein M.R., Mascitelli L., Pezzetta F. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;71:956&#x2013;957. doi: 10.1212/01.wnl.0000327866.54482.f1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000327866.54482.f1</ArticleId><ArticleId IdType="pubmed">18794503</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Deng J., Jaffa M., Cudkowicz M.E., Wills A.M. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20&#x2013;24. doi: 10.1002/mus.22114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.22114</ArticleId><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergani A., Oudart H., Gonzalez De Aguilar J.L., Fricker B., Ren&#xe9; F., Hocquette J.F., Meininger V., Dupuis L., Loeffler J.P. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res. 2007;48:1571&#x2013;1580. doi: 10.1194/jlr.M700017-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M700017-JLR200</ArticleId><ArticleId IdType="pmc">PMC1974855</ArticleId><ArticleId IdType="pubmed">17438338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O., Meyer H.E., Stigum H., Holm&#xf8;y T. High BMI is associated with low ALS risk: A population-based study. Neurology. 2019;93:e424&#x2013;e432. doi: 10.1212/WNL.0000000000007861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich-Slotky R., Andrews J., Cheng B., Buchsbaum R., Levy D., Kaufmann P., Thompson J.L. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph. Lateral Scler. Front. Degener. 2013;14:212&#x2013;216. doi: 10.3109/21678421.2013.770028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.770028</ArticleId><ArticleId IdType="pubmed">23452274</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse van Mantgem M.R., van Rheenen W., Hackeng A.V., van Es M.A., Veldink J.H., van den Berg L.H., van Eijk R.P.A. Association Between Serum Lipids and Survival in Patients with Amyotrophic Lateral Sclerosis: A Meta-analysis and Population-Based Study. Neurology. 2023;100:e1062&#x2013;e1071. doi: 10.1212/WNL.0000000000201657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000201657</ArticleId><ArticleId IdType="pmc">PMC9990853</ArticleId><ArticleId IdType="pubmed">36460467</ArticleId></ArticleIdList></Reference><Reference><Citation>Trostchansky A. Overview of Lipid Biomarkers in Amyotrophic Lateral Sclerosis (ALS) Adv. Exp. Med. Biol. 2019;1161:233&#x2013;241. doi: 10.1007/978-3-030-21735-8_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-21735-8_18</ArticleId><ArticleId IdType="pubmed">31562633</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ Clin. Res. Ed. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ Clin. Res. Ed. 2003;327:557&#x2013;560. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard B.G., Langsted A., Mora S., Kolovou G., Baum H., Bruckert E., Watts G.F., Sypniewska G., Wiklund O., Bor&#xe9;n J., et al. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur. Heart J. 2016;37:1944&#x2013;1958. doi: 10.1093/eurheartj/ehw152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw152</ArticleId><ArticleId IdType="pmc">PMC4929379</ArticleId><ArticleId IdType="pubmed">27122601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.M., Highton-Williamson E., Caga J., Thornton N., Ramsey E., Zoing M., Kim W.S., Halliday G.M., Piguet O., Hodges J.R., et al. Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. J. Alzheimer&#x2019;s Dis. 2018;61:773&#x2013;783. doi: 10.3233/JAD-170660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170660</ArticleId><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C., Chen L., Zhan Y., Termorshuizen J., Yin L., Fang F. Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology. 2020;94:e1835&#x2013;e1844. doi: 10.1212/WNL.0000000000009322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="pubmed">32221024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D., Hammar N., Malmstr&#xf6;m H., Ingre C., Jungner I., Ye W., Fang F., Walldius G. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann. Neurol. 2017;81:718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Che&#x142;stowska B., Ku&#x17a;ma-Kozakiewicz M. Biochemical parameters in determination of nutritional status in amyotrophic lateral sclerosis. Neurol. Sci. 2020;41:1115&#x2013;1124. doi: 10.1007/s10072-019-04201-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04201-x</ArticleId><ArticleId IdType="pubmed">31897946</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.W., Kim S.M., Kim H.J., Kim J.E., Park K.S., Kim S.H., Lee K.W., Sung J.J. Hypolipidemia in patients with amyotrophic lateral sclerosis: A possible gender difference? J. Clin. Neurol. 2013;9:125&#x2013;129. doi: 10.3988/jcn.2013.9.2.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.125</ArticleId><ArticleId IdType="pmc">PMC3633190</ArticleId><ArticleId IdType="pubmed">23626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Rosi E., Fini N., Fasano A., Raggi S., Fantuzzi A.L., Bedogni G. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol. Sci. 2017;38:2177&#x2013;2182. doi: 10.1007/s10072-017-3138-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3138-8</ArticleId><ArticleId IdType="pubmed">28980128</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R., Guo X., Chen X., Zheng Z., Wei Q., Cao B., Zeng Y., Shang H. The serum lipid profiles of amyotrophic lateral sclerosis patients: A study from south-west China and a meta-analysis. Amyotroph. Lateral Scler. Front. Degener. 2015;16:359&#x2013;365. doi: 10.3109/21678421.2015.1047454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1047454</ArticleId><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R., Kurihara M., Ogawa N., Kitamura A., Yamakawa I., Bamba S., Sanada M., Sasaki M., Urushitani M. Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: Roles of sex and hypermetabolism. Sci. Rep. 2022;12:1826. doi: 10.1038/s41598-022-05714-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05714-w</ArticleId><ArticleId IdType="pmc">PMC8814149</ArticleId><ArticleId IdType="pubmed">35115598</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson A.G., Talbot K., Turner M.R. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2022;93:75&#x2013;81. doi: 10.1136/jnnp-2021-327133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327133</ArticleId><ArticleId IdType="pmc">PMC8685635</ArticleId><ArticleId IdType="pubmed">34518331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatsuji H., Araki A., Hashizume A., Hijikata Y., Yamada S., Inagaki T., Suzuki K., Banno H., Suga N., Okada Y., et al. Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J. Neurol. 2017;264:839&#x2013;847. doi: 10.1007/s00415-017-8405-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8405-3</ArticleId><ArticleId IdType="pubmed">28229243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballantyne C.M., Podet E.J., Patsch W.P., Harati Y., Appel V., Gotto A.M., Jr., Young J.B. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989;262:53&#x2013;56. doi: 10.1001/jama.1989.03430010065032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1989.03430010065032</ArticleId><ArticleId IdType="pubmed">2733125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A., Acimovic J., L&#xf6;vgren-Sandblom A., Parini P., Andersen P.M., Bj&#xf6;rkhem I. Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS ONE. 2014;9:e113619. doi: 10.1371/journal.pone.0113619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113619</ArticleId><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja N.A., van der Schouw Y.T., Fischer K., Sizoo E.M., Huisman M.H., Veldink J.H., Van den Berg L.H. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2011;82:638&#x2013;642. doi: 10.1136/jnnp.2010.236752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Deguise M.O., Baranello G., Mastella C., Beauvais A., Michaud J., Leone A., De Amicis R., Battezzati A., Dunham C., Selby K., et al. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann. Clin. Transl. Neurol. 2019;6:1519&#x2013;1532. doi: 10.1002/acn3.50855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50855</ArticleId><ArticleId IdType="pmc">PMC6689695</ArticleId><ArticleId IdType="pubmed">31402618</ArticleId></ArticleIdList></Reference><Reference><Citation>Darios F., Mochel F., Stevanin G. Lipids in the Physiopathology of Hereditary Spastic Paraplegias. Front. Neurosci. 2020;14:74. doi: 10.3389/fnins.2020.00074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00074</ArticleId><ArticleId IdType="pmc">PMC7059351</ArticleId><ArticleId IdType="pubmed">32180696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Guevara E., C&#xe1;rdenas G., P&#xe9;rez-Severiano F., Mart&#xed;nez-Lazcano J.C. Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington&#x2019;s Disease. Mov. Disord. 2020;35:1113&#x2013;1127. doi: 10.1002/mds.28089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28089</ArticleId><ArticleId IdType="pubmed">32410324</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanning S., Selkoe D., Dettmer U. Parkinson&#x2019;s disease: Proteinopathy or lipidopathy? NPJ Parkinson&#x2019;s Dis. 2020;6:3. doi: 10.1038/s41531-019-0103-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-019-0103-7</ArticleId><ArticleId IdType="pmc">PMC6941970</ArticleId><ArticleId IdType="pubmed">31909184</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchsinger J.A., Cheng D., Tang M.X., Schupf N., Mayeux R. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2012;26:101&#x2013;105. doi: 10.1097/WAD.0b013e318222f0d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e318222f0d4</ArticleId><ArticleId IdType="pmc">PMC3358415</ArticleId><ArticleId IdType="pubmed">21666429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolppanen A.M., Ngandu T., K&#xe5;reholt I., Laatikainen T., Rusanen M., Soininen H., Kivipelto M. Midlife and late-life body mass index and late-life dementia: Results from a prospective population-based cohort. J. Alzheimer&#x2019;s Dis. JAD. 2014;38:201&#x2013;209. doi: 10.3233/JAD-130698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130698</ArticleId><ArticleId IdType="pubmed">23948937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Coburn K.M., Vevea J.L. Publication bias as a function of study characteristics. Psychol. Methods. 2015;20:310&#x2013;330. doi: 10.1037/met0000046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/met0000046</ArticleId><ArticleId IdType="pubmed">26348731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi P., Polidori M.C., Metastasio A., Mariani E., Mattioli P., Cherubini A., Catani M., Cecchetti R., Senin U., Mecocci P. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2003;24:915&#x2013;919. doi: 10.1016/S0197-4580(03)00031-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00031-9</ArticleId><ArticleId IdType="pubmed">12928050</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevic Z., Kostic-Dedic S., Peric S., Dedic V., Basta I., Rakocevic-Stojanovic V., Lavrnic D. Prognostic factors and survival of ALS patients from Belgrade, Serbia. Amyotroph. Lateral Scler. Front. Degener. 2016;17:508&#x2013;514. doi: 10.1080/21678421.2016.1195410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1195410</ArticleId><ArticleId IdType="pubmed">27315438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip P.K., Pizzasegola C., Gladman S., Biggio M.L., Marino M., Jayasinghe M., Ullah F., Dyall S.C., Malaspina A., Bendotti C., et al. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS ONE. 2013;8:e61626. doi: 10.1371/journal.pone.0061626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0061626</ArticleId><ArticleId IdType="pmc">PMC3631166</ArticleId><ArticleId IdType="pubmed">23620776</ArticleId></ArticleIdList></Reference><Reference><Citation>The Amyotrophic Lateral Sclerosis Functional Rating Scale Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch. Neurol. 1996;53:141&#x2013;147. doi: 10.1001/archneur.1996.00550020045014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1996.00550020045014</ArticleId><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Nakamura Y., Kiyozuka T., Aoyagi J., Hirayama T., Nagata R., Ito H., Iwamoto K., Murata K., Yoshii Y., et al. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson&#x2019;s disease: Changes linked to disease progression. Neuro-Degener. Dis. 2011;8:252&#x2013;258. doi: 10.1159/000323265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323265</ArticleId><ArticleId IdType="pubmed">21282940</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Cao D., Kim H., Lester R., Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol. 2006;60:729&#x2013;739. doi: 10.1002/ana.21053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21053</ArticleId><ArticleId IdType="pubmed">17192930</ArticleId></ArticleIdList></Reference><Reference><Citation>Polidori M.C. Oxidative stress and risk factors for Alzheimer&#x2019;s disease: Clues to prevention and therapy. J. Alzheimer&#x2019;s Dis. 2004;6:185&#x2013;191. doi: 10.3233/JAD-2004-6211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2004-6211</ArticleId><ArticleId IdType="pubmed">15096703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Luo X., Chen X., Shang H. Lipid Profile in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Front. Neurol. 2020;11:567753. doi: 10.3389/fneur.2020.567753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.567753</ArticleId><ArticleId IdType="pmc">PMC7593382</ArticleId><ArticleId IdType="pubmed">33178110</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E., Larrea D., Yun T., Xu Y., Hupf J., Zandkarimi F., Chan R.B., Mitsumoto H. Lipidomics study of plasma from patients suggest that ALS and PLS are part of a continuum of motor neuron disorders. Sci. Rep. 2021;11:13562. doi: 10.1038/s41598-021-92112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-92112-3</ArticleId><ArticleId IdType="pmc">PMC8245424</ArticleId><ArticleId IdType="pubmed">34193885</ArticleId></ArticleIdList></Reference><Reference><Citation>Alessenko A.V., Gutner U.A., Shupik M.A. Involvement of Lipids in the Pathogenesis of Amyotrophic Lateral Sclerosis. Life. 2023;13:510. doi: 10.3390/life13020510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13020510</ArticleId><ArticleId IdType="pmc">PMC9966871</ArticleId><ArticleId IdType="pubmed">36836867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jov&#xe9; M., Mota-Martorell N., Torres P., Portero-Otin M., Ferrer I., Pamplona R. New insights into human prefrontal cortex aging with a lipidomics approach. Expert Rev. Proteom. 2021;18:333&#x2013;344. doi: 10.1080/14789450.2021.1940142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2021.1940142</ArticleId><ArticleId IdType="pubmed">34098823</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q., He Z., Zubkov D., Huang S., Kurochkin I., Yang X., Halene T., Willmitzer L., Giavalisco P., Akbarian S., et al. Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders. Mol. Psychiatry. 2020;25:2952&#x2013;2969. doi: 10.1038/s41380-018-0200-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0200-8</ArticleId><ArticleId IdType="pmc">PMC7577858</ArticleId><ArticleId IdType="pubmed">30089790</ArticleId></ArticleIdList></Reference><Reference><Citation>Speakman J.R., Westerterp K.R. Associations between energy demands, physical activity, and body composition in adult humans between 18 and 96 y of age. Am. J. Clin. Nutr. 2010;92:826&#x2013;834. doi: 10.3945/ajcn.2009.28540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2009.28540</ArticleId><ArticleId IdType="pubmed">20810973</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y., Park J., Kim Y., Baek H., Kim S.H. Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients. Nutrition. 2015;31:1362&#x2013;1367. doi: 10.1016/j.nut.2015.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2015.05.025</ArticleId><ArticleId IdType="pubmed">26429656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhun J., Moon J., Kim S.Y., Cho K.H., Na H.S., Choi J., Jung Y.J., Song K.Y., Min J.K., Cho M.L. Rebamipide treatment ameliorates obesity phenotype by regulation of immune cells and adipocytes. PLoS ONE. 2022;17:e0277692. doi: 10.1371/journal.pone.0277692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0277692</ArticleId><ArticleId IdType="pmc">PMC9794058</ArticleId><ArticleId IdType="pubmed">36574392</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy-Corchuelo J.M., Fern&#xe1;ndez-Beltr&#xe1;n L.C., Ali Z., Gil-Moreno M.J., L&#xf3;pez-Carbonero J.I., Guerrero-Sola A., Larrad-Sainz A., Matias-Guiu J., Matias-Guiu J.A., Cunningham T.J., et al. Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders. Biomedicines. 2022;10:1105. doi: 10.3390/biomedicines10051105.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051105</ArticleId><ArticleId IdType="pmc">PMC9138405</ArticleId><ArticleId IdType="pubmed">35625841</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Wills A.M. High-fat and ketogenic diets in amyotrophic lateral sclerosis. J. Child Neurol. 2013;28:989&#x2013;992. doi: 10.1177/0883073813488669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073813488669</ArticleId><ArticleId IdType="pmc">PMC4438106</ArticleId><ArticleId IdType="pubmed">23666040</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Lumbroso S., Cazeneuve C., Mouzat K., Camu W., Vourc&#x2019;h P. Pre-symptomatic diagnosis in ALS. Rev. Neurol. 2020;176:166&#x2013;169. doi: 10.1016/j.neurol.2019.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.07.027</ArticleId><ArticleId IdType="pubmed">31932031</ArticleId></ArticleIdList></Reference><Reference><Citation>Amtmann D., Weydt P., Johnson K.L., Jensen M.P., Carter G.T. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am. J. Hosp. Palliat. Care. 2004;21:95&#x2013;104. doi: 10.1177/104990910402100206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/104990910402100206</ArticleId><ArticleId IdType="pubmed">15055508</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Toivonen J.M., Moreno-Mart&#xed;nez L., de la Torre M., Moreno-Garc&#xed;a L., L&#xf3;pez-Royo T., Molina N., Zaragoza P., Calvo A.C., Osta R. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy. Br. J. Pharmacol. 2021;178:1279&#x2013;1297. doi: 10.1111/bph.15276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15276</ArticleId><ArticleId IdType="pubmed">32986860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarantino N., Canfora I., Camerino G.M., Pierno S. Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle. Cells. 2022;11:415. doi: 10.3390/cells11030415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11030415</ArticleId><ArticleId IdType="pmc">PMC8834084</ArticleId><ArticleId IdType="pubmed">35159225</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino G.M., De Bellis M., Conte E., Liantonio A., Musaraj K., Cannone M., Fonzino A., Giustino A., De Luca A., Romano R., et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. Toxicol. Appl. Pharmacol. 2016;306:36&#x2013;46. doi: 10.1016/j.taap.2016.06.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2016.06.032</ArticleId><ArticleId IdType="pubmed">27377005</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>